MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-24-2025
NovoCure Limited Revenue 2011-2025 | NVCR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue NovoCure Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 605 M | 509 M | 538 M | 535 M | 144 M | 351 M | 248 M | 177 M | 82.9 M | 33.1 M | 15.5 M | 10.4 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 605 M | 10.4 M | 271 M |
Quarterly Revenue NovoCure Limited
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 159 M | 155 M | - | 155 M | 150 M | 139 M | - | 127 M | 126 M | 122 M | - | 131 M | 141 M | 138 M | 133 M | 134 M | 134 M | 135 M | 144 M | 494 M | 494 M | 494 M | 99.2 M | 351 M | 351 M | 351 M | 69.7 M | 248 M | 248 M | 52.1 M | 53.7 M | 50.1 M | 38.4 M | 34.9 M | 30.2 M | 82.9 M | 82.9 M | 82.9 M | 12.4 M | 33.1 M | 33.1 M | 33.1 M | - | 4.37 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 494 M | 4.37 M | 151 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Health care industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anthem
ANTM
|
177 B | - | -2.32 % | $ 107 B |  USA |
 |
Cigna Corporation
CI
|
247 B | $ 273.87 | 0.59 % | $ 75 B | USA |
 |
Triple-S Management Corporation
GTS
|
3.7 B | - | 0.28 % | $ 847 M | USA |
 |
Magellan Health, Inc.
MGLN
|
4.58 B | - | -0.19 % | $ 2.49 B | USA |
 |
Centene Corporation
CNC
|
163 B | $ 40.83 | 0.91 % | $ 21.3 B | USA |
 |
CVS Health Corporation
CVS
|
373 B | $ 78.97 | -2.3 % | $ 99.4 B | USA |
 |
Humana
HUM
|
118 B | $ 268.21 | 0.65 % | $ 32.3 B | USA |
 |
Molina Healthcare
MOH
|
40.6 B | $ 168.9 | 1.2 % | $ 9.69 B | USA |
 |
UnitedHealth Group Inc.
UNH
|
400 B | $ 340.98 | 1.26 % | $ 314 B | USA |